US Parkinson's Disease Therapeutics Market Overview
As per MRFR analysis, the US Parkinson's Disease Therapeutics Market Size was estimated at 1.24 (USD Billion) in 2023. The US Parkinson's Disease Therapeutics Market Industry is expected to grow from 1.5(USD Billion) in 2024 to 3.5 (USD Billion) by 2035. The US Parkinson's Disease Therapeutics Market CAGR (growth rate) is expected to be around 8.007% during the forecast period (2025 - 2035).
Key US Parkinson's Disease Therapeutics Market Trends Highlighted
The US Parkinson's Disease Therapeutics Market is experiencing notable trends driven by an aging population and increasing awareness of the disease. As the baby boomer generation ages, the prevalence of Parkinson's disease is expected to rise, leading to a greater demand for effective therapeutic options. Additionally, advancements in research and technology are fostering the development of innovative treatments, including disease-modifying therapies and neuroprotective strategies, creating hope for improved patient outcomes. Key market drivers encompass government initiatives and funding aimed at enhancing research and awareness regarding Parkinson's disease.
The National Institutes of Health (NIH) and other organizations are significantly contributing to research efforts, aiming to unlock better treatment solutions and understanding of the disease. Furthermore, pharmaceutical companies are actively investing in pipeline candidates, focusing on both symptomatic relief and potential disease-modifying therapies, which are expected to transform patient care in the near future. Opportunities to be captured include the development of wearable technologies and digital health tools that cater to patient needs and improve treatment adherence.
As personalized medicine continues to gain traction, there is a significant opportunity for therapies tailored to individual genetic profiles and lifestyle factors.Additionally, the growing interest in collaborations among academic institutions, biotech firms, and pharmaceutical companies presents potential for accelerated research and the introduction of groundbreaking therapies to the market. Recent trends indicate a rise in clinical trials for novel therapies, which encourages innovation in treatment approaches. The increasing integration of telehealth services is also noteworthy, enabling better access to specialists for patients who may have mobility challenges. Overall, the evolving landscape of the US Parkinson's Disease Therapeutics Market highlights substantial growth potential shaped by these trends and market drivers.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
US Parkinson's Disease Therapeutics Market Drivers
Increase in Aging Population
The United States is witnessing a significant increase in its aging population, which is a major driver for the US Parkinson's Disease Therapeutics Market Industry. According to data from the U.S. Census Bureau, the number of individuals aged 65 and older is projected to rise from approximately 54 million in 2020 to around 80 million by 2040. This demographic shift indicates a higher prevalence of Parkinson's disease, as the condition is primarily diagnosed in individuals over the age of 60.
The American Parkinson Disease Association and similar organizations provide substantial resources and support for affected individuals, contributing to increased awareness and demand for effective therapeutics in the market. Moreover, with the growing incidence of age-related neurological disorders, the potential for new therapeutic developments presents a significant opportunity for market growth.
Advancements in Research and Development
The US Parkinson's Disease Therapeutics Market Industry is experiencing remarkable growth driven by advancements in Research and Development (R&D) in therapeutics and drug formulations. Increased funding for neurological research, particularly from institutions such as the National Institutes of Health (NIH), has led to breakthroughs in understanding the pathophysiology of Parkinson's disease. The NIH reported an increase in funding for Parkinson's disease research from $175 million in 2015 to nearly $300 million in 2022.
This upward trend in investment is fostering innovation in drug development, resulting in more effective treatment options. Furthermore, collaborations between pharmaceutical companies and academic institutions enhance the development pipeline, ensuring a steady introduction of new therapies to the market.
Growing Patient Awareness and Advocacy
Awareness about Parkinson's disease and the importance of treatment options is increasing amongst patients and caregivers in the United States, significantly impacting the US Parkinson's Disease Therapeutics Market Industry. Organizations such as the Parkinson's Foundation and the Michael J. Fox Foundation are actively campaigning to inform the public about Parkinson's disease, its symptoms, and available treatments.
These advocacy efforts have increased understanding and recognition of the disease, resulting in more patients seeking medical advice and therapeutic options.According to recent surveys, about 92% of individuals diagnosed with Parkinson's disease are actively seeking information on treatment options, highlighting a growing demand for effective therapeutics to manage symptoms and improve quality of life.
Investment in Innovative Therapeutics
Significant investment in innovative therapeutic approaches for Parkinson's disease is becoming a prominent driver in the US Parkinson's Disease Therapeutics Market Industry. Biopharmaceutical companies are exploring novel therapies, including gene therapy, stem cell treatments, and advanced neuroprotective agents to revolutionize how Parkinson's is treated.
The Pharmaceutical Research and Manufacturers of America reported that in 2022, more than 60 potential new therapies targeting neurological disorders were in various stages of development within the U.S., with many focusing specifically on Parkinson's disease.This surge in innovation, combined with favorable regulatory environments encouraged by the U.S. Food and Drug Administration, elevates the potential for rapid market expansion as new, effective treatments are introduced.
US Parkinson's Disease Therapeutics Market Segment Insights:
Parkinson's Disease Therapeutics Market Treatment Type Insights
The US Parkinson's Disease Therapeutics Market has seen significant advancements in recent years, particularly in the Treatment Type segment, which encompasses various approaches to managing the disease. This market is driven by an increasing prevalence of Parkinson's disease, with the growing aging population contributing as a major factor. Among the various treatment types, Medication stands out as a foundational element of therapy. It involves pharmacological agents designed to alleviate symptoms and improve the quality of life for patients. The rise of specific drug formulations enables tailored treatments that can address the unique needs of individual patients.
On the other hand, Surgical Therapy represents a crucial alternative treatment option, primarily utilized for patients who do not respond adequately to medication. Procedures such as deep brain stimulation have gained traction, demonstrating efficacy in managing motor symptoms, proving to be a pivotal part of patient care for more advanced stages of the disease. This option has become increasingly significant as it allows patients to maintain a greater degree of independence and functionality, directly impacting their day-to-day lives.
Moreover, Carbidopa/Levodopa Enteral Suspension is recognized as an innovative therapy that provides continuous dopaminergic stimulation. This delivery method helps to minimize peak-dose dyskinesias, offering more stable control of symptoms. It is particularly important as it represents a shift towards personalized medicine in the treatment of Parkinson's disease, responding to the specific needs of patients as their disease progresses. The combination of these treatments illustrates a multi-faceted approach to managing Parkinson's disease, addressing the complexity and variability of symptoms that patients experience.
Additionally, trends such as the increasing integration of technology in therapeutics and patient monitoring systems are likely to bolster treatment efficacy and improve patient outcomes. However, despite the promising advancements in Treatment Type, challenges such as high costs and access disparities remain hurdles that need to be addressed to ensure that all patients have equitable access to these critical therapies. As the US Parkinson's Disease Therapeutics Market continues to evolve, the emphasis on diverse and individualized treatment options will play a vital role in enhancing the care and quality of life for those living with Parkinson's disease.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Parkinson's Disease Therapeutics Market End User Insights
The US Parkinson's Disease Therapeutics Market is significantly shaped by its End User segment, which plays a crucial role in the delivery of care and research related to the disease. Hospitals and clinics are essential for the diagnosis and management of Parkinson's Disease, providing patients with specialized treatment options and access to healthcare professionals. This segment often drives patient engagement and advances therapeutic innovations through direct interactions with practitioners.
On the other hand, academic and industrial research institutions contribute to the development of new therapies and treatment strategies, focusing on understanding the disease's underlying mechanisms and exploring novel drug discoveries.These research facilities often collaborate with healthcare providers to translate findings into clinical settings, ensuring that therapeutic advancements reach patients effectively.
The synergy between these sub-segments enhances the overall landscape of the US Parkinson's Disease Therapeutics Market, fostering an environment where patient care and scientific discovery thrive. This integration of healthcare delivery and research initiatives represents a significant opportunity for growth and innovation in addressing the needs of individuals living with Parkinson's Disease.
US Parkinson's Disease Therapeutics Market Key Players and Competitive Insights:
The competitive landscape of the US Parkinson's Disease Therapeutics Market is characterized by a blend of established pharmaceutical companies and emerging biotech firms. This market is rapidly evolving, driven by an increasing prevalence of Parkinson's disease, ongoing research efforts, and advancements in therapeutic interventions.
Companies are focused on developing innovative treatments, including orally administered drugs, injectables, and future therapies targeting specific disease mechanisms. There is a strong emphasis on research and development strategies to enhance patient outcomes and address the unmet needs of Parkinson's disease management. Collaboration among stakeholders, including academic institutions and regulatory bodies, plays a crucial role in bringing effective therapies to market and navigating the complexities associated with Parkinson's disease treatment.
Merck and Co is a prominent player in the US Parkinson's Disease Therapeutics Market, leveraging its extensive research capabilities and global presence to strengthen its market position. While its portfolio shows a commitment to neurological health, the company's focus on strategic partnerships and collaborations with academic institutions has amplified its innovative therapy development. Merck and Co’s robust clinical trial programs and investment in next-generation therapies showcase its dedication to addressing Parkinson's disease. The company's strengths lie in its well-established reputation, advanced manufacturing capabilities, and comprehensive distribution networks, allowing it to efficiently reach healthcare providers and patients across the United States. Such competitive advantages enable Merck and Co to maintain a significant role within a market striving for advancements in treatment approaches.
Teva Pharmaceutical Industries has also carved a niche within the US Parkinson's Disease Therapeutics Market, mainly through a portfolio that includes key products designed to alleviate the symptoms of the disease and enhance the quality of life for patients. The company's presence in the market is underpinned by a range of generic treatments as well as branded therapies, which allows Teva to cater to various segments of the patient population.
Teva's strengths include its commitment to research and development that continually seeks innovative solutions, along with its operational efficiencies that contribute to cost-effective treatment options. Over the years, Teva has pursued strategic mergers and acquisitions to bolster its pipeline and expand its footprint in the neurology sector, further solidifying its competitive edge in the US market for Parkinson's disease therapeutics. This approach has not only enriched Teva's offering but also positioned it as a formidable competitor in an increasingly complex and competitive landscape.
Key Companies in the US Parkinson's Disease Therapeutics Market Include:
US Parkinson's Disease Therapeutics Market Industry Developments
The US Parkinson's Disease Therapeutics Market has seen significant developments recently. In October 2023, neurodegenerative disease-focused companies like Neurocrine Biosciences and AbbVie continue to advance their products through clinical trials, enhancing patient care and treatment options. Additionally, in September 2023, Teva Pharmaceutical Industries announced progress in its research for novel formulations aimed at improving patient adherence and outcomes. Moreover, Merck and Co has invested heavily in Research and Development strategies targeting biomarker-driven therapy as a means to personalize treatment approaches.
In terms of mergers and acquisitions, Horizon Therapeutics established a collaboration with another pharmaceutical entity in August 2023 to expand its product portfolio related to Parkinson's therapy, showcasing an upward trend in consolidation efforts among major players. Companies like GlaxoSmithKline and Bristol Myers Squibb are also actively engaged in expanding their therapeutic formulations to cater to the growing demand. The overall market valuation for the Parkinson's Disease therapeutics has shown a steady increase, driven by innovation and a rising patient population within the U.S. over the past two years.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 1.24(USD Billion) |
| MARKET SIZE 2024 | 1.5(USD Billion) |
| MARKET SIZE 2035 | 3.5(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.007% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Billion |
| KEY COMPANIES PROFILED | Merck and Co, Teva Pharmaceutical Industries, Acorda Therapeutics, Bristol Myers Squibb, GlaxoSmithKline, Cortexyme, Neurocrine Biosciences, Horizon Therapeutics, Revance Therapeutics, Zynerba Pharmaceuticals, Pfizer, Amgen, AbbVie, Sanofi, UCB |
| SEGMENTS COVERED | Treatment Type, End User |
| KEY MARKET OPPORTUNITIES | Novel drug development advancements, Non-invasive treatment technologies, Personalized medicine approaches, Telehealth integration in therapies, Increasing awareness and early diagnosis |
| KEY MARKET DYNAMICS | Rising geriatric population, Increasing R&D investment, Growing demand for symptom management, Advancements in drug formulations, Healthcare policy reforms |
| COUNTRIES COVERED | US |
Frequently Asked Questions (FAQ) :
The expected market size of the US Parkinson's Disease Therapeutics Market in 2024 is valued at 1.5 billion USD.
By 2035, the market size of the US Parkinson's Disease Therapeutics Market is projected to reach 3.5 billion USD.
The expected CAGR for the US Parkinson's Disease Therapeutics Market from 2025 to 2035 is 8.007%.
In 2024, the largest market share is held by the Medication segment, valued at 0.9 billion USD.
The Carbidopa/Levodopa Enteral Suspension segment is expected to be valued at 0.5 billion USD by 2035.
Major players in the market include Merck and Co, Teva Pharmaceutical Industries, and Acorda Therapeutics, among others.
Growth opportunities in the market are driven by increasing patient population and advancements in treatment options.
The expected market size for Surgical Therapy in 2024 is 0.4 billion USD.
Emerging trends include the development of personalized medicine and novel therapeutic approaches in treatment.
All segments, including Medication and Surgical Therapy, are expected to experience positive growth rates from 2025 to 2035.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
